Calliditas Therapeutics announced that the European Commission has granted a full marketing authorization for Kinpeygo for the treatment of adults with primary immunoglobulin A nephropathy. The European Commission has granted a full marketing authorization of Kinpeygo. Kinpeygo is marketed in in the European Union and UK exclusively by Calliditas’ commercial partner, Stada Arzneimittel. This approval triggers a milestone payment of EUR 10M to Calliditas, which will be recognized as revenue in Q3.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALT:
- Calliditas says partner initiated Phase III Nefecon trial in Japan
- Calliditas Therapeutics announces USPTO issues patent for setanaxib
- Calliditas Therapeutics’ Annual Meeting Highlights
- Calliditas Therapeutics downgraded to Hold from Buy at Pareto
- Calliditas Therapeutics downgraded to Hold from Buy at SEB Equities